Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
RESEARCH TOOLSreports
Kiora Pharmaceuticals (KPRX) Stock Price & Analysis
392 Followers
KPRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.45 - $2.70
Previous Close$0.5
Volume28.61K
Average Volume (3M)255.64K
Market Cap
$13.15M
Enterprise Value$7.77M
Total Cash (Recent Filing)$5.40M
Total Debt (Recent Filing)$18.73K
Price to Earnings (P/E)-0.2
Beta-0.14
Next Earnings
Aug 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.98
Shares Outstanding26,256,197
10 Day Avg. Volume154,777
30 Day Avg. Volume255,644
Standard Deviation0.27
R-Squared0.00132
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-19.10
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.51
Forecast
1Y Price Target
$2.50Price Target Upside411.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Kiora Pharmaceuticals News
PremiumCompany Announcements
Kiora Pharmaceuticals Unveils Updated Investor Presentation
PremiumCompany Announcements
Kiora Pharmaceuticals Announces Securities Purchase Agreements
PremiumCompany Announcements
Kiora Pharmaceuticals Reveals TOI Agreement and Presentation
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessKIO-301 has demonstrated meaningful vision improvement in clinical trials, with significant visual field enhancements and visual acuity improvements, indicating its potential as an effective treatment for retinitis pigmentosa.
Financial StabilityRecent financing achievements, including a closed financing round and a substantial private placement, have bolstered Kiora's cash reserves, ensuring the company's operational stability and funding for ongoing clinical trials.
Strategic PartnershipsKiora's new partnership with a leading French ophthalmology firm and the deal with Laboratoires Théa for commercial rights signal strong industry confidence in KIO-301 and potential future revenue through milestone payments and royalties.
Bears Say
Earnings ReportKiora's recent earnings report shows a net loss of $5.8 million, which may raise concerns about the company's profitability and financial health.
Financial StabilityThe company's need to raise additional capital within the next 12 months suggests it may be facing liquidity issues, which could be a red flag for investors.
Price Target AdjustmentAnalyst adjusts the 12-month price target for a stock to $2 from $3.50, indicating potential lowered expectations for the stock's future performance.
---
Ownership Overview
21.60% Insiders
0.28% Mutual Funds
8.85% Other Institutional Investors
69.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $0.45 and its highest was $2.70 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Currently, no data Available
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 91 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on Mar 25, 2024. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.39 by $0.1.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 26,256,197 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.39. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
---
Kiora Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (411.25% Upside)
$2.50 (411.25% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 10.5%
Last 30 Days ▼ 10.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.84%
12-Months-Change
Fundamentals
Return on Equity
-142.88%
Trailing 12-Months
Asset Growth
-26.59%
Trailing 12-Months
Company Description
Kiora Pharmaceuticals
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
---
KPRX Stock 12 Month Forecast
Average Price Target
$2.50
▲(411.25% Upside)
Technical Analysis
Best Analysts Covering KPRX
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-67.81%
reiterated a buy rating last month
Copying Yi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -67.81% per trade.
---